


## R&D Pipeline



antibody



protein



small molecule

© New Molecular Entity

➔ Updated since Dec. 31, 2022



Updated since Jun. 30, 2023

### Nephrology


As of Sep 30, 2023

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KHK7580 Evocalcet Oral	Calcimimetic	Secondary Hyperparathyroidism	CN KR TW	➔					[Mitsubishi Tanabe Pharma] product name in Japan: Orkedia
KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Preeclampsia	JP	➔					[In-House] product name in Japan: Acoalan
KHK7791 Tenapanor Hydrochloride Oral	NHE3 Inhibitor	Hyperphosphatemia in Patients on Dialysis	JP	➔					[Ardelyx]
KRN1493 Cinacalcet Hydrochloride Oral	Calcimimetic	Primary Hyperparathyroidism	HK	➔					[NPS Pharmaceuticals] product name in Japan: Regpara

### Oncology

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Mycosis Fungoides and Sézary Syndrome	KW	➔					[In-House] POTELLIGENT product name in Japan, US and Europe: Poteligeo
			IL	➔					
			ME	➔					
			RS	➔					
KRN125 Pegfilgrastim Injection	Long-Acting Granulocyte Colony- Stimulating Factor	Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Blood Stem Cell Transplantation	JP	➔					[Amgen K-A] product name in Japan: G-Lasta

## R&D Pipeline



antibody



protein



small molecule

© New Molecular Entity



Updated since Dec. 31, 2022



Updated since Jun. 30, 2023

### Immunology/Allergy

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Ankylosing Spondylitis	TH	→					[Amgen K-A] product name in Japan and Asia: Lumicef
		Non-radiographic Axial Spondyloarthritis	TH	→					
		Palmoplantar Pustulosis	JP	→					
		Systemic Sclerosis	JP	→					
©KHK4083/AMG 451 Rocatinlimab Injection	Anti-OX40 Fully Human Antibody	Atopic Dermatitis	JP NA Europe Middle East CN Asia Oceania others	→					[In-House] POTELLIGENT Fully human antibody production technology Collaboration agreement with Amgen for the development of KHK4083/AMG 451 in all the countries except for Japan.
©KK4277 Injection		Autoimmune Disease	JP Asia	→					[SBI Biotech]

### Other

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KRN23 Burosumab Injection	Anti-FGF23 Fully Human Antibody	Tumor Induced Osteomalacia (TIO)	OM QA UAE	→					[In-House] Fully human antibody production technology Jointly Developed with Ultragenyx in US and Europe product name in Japan, US and Europe: Crysvita
			KW BH	→					
			RS ME	→					
		X-linked Hypophosphatemia (XLH)	MO	→					
			MK	→					
			RS ME	→					
AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Aplastic Anemia Previously Untreated with Immunosuppressive Therapy	JP	→					[Amgen K-A] product name in Japan: Romiplate
KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	Europe	→					[In-House] product name in Japan: Acoalan
KHK4951 Tivozanib Ophthalmic	VEGF Receptor Tyrosine Kinase Inhibitor	Neovascular (wet) Age-Related Macular Degeneration	JP	→					[In-House]

Note: Our main progress from September 30, 2023 is as follows.

·We decided to discontinue the development of KW-3357 (product name in Japan: Acoalan) for treatment for preeclampsia in the nephrology field.